Background: To investigate prognosis and effects of first-line therapy in elderly primary central nervous system lymphoma (PCNSL) patients.
extranodal lymphomas [1] . The incidence of PCNSL in immunocompetent patients has been steadily increasing over the last 30 years [2, 3] . High-dose methotrexate (HD-MTX) in combination with HD-cytarabine (HD-AraC) is the backbone of current treatment [4] . A recent randomized, controlled trial investigated the role of whole-brain radiotherapy (WBRT) as consolidation compared with no consolidation therapy, suggesting that WBRT does not prolong survival but enhances disease control [5] . However, despite treatment improvement, the prognosis of PCNSL patients is still poor compared with systemic NHL [6] .
Patients older than 60 years account for 50% of all PCNSL cases. Although elderly patients are able to tolerate aggressive systemic chemotherapy [7] , they have an inferior prognosis compared with younger patients and are more seriously affected by iatrogenic toxicity, especially neurological side-effects following WBRT [8] ; therefore, they represent a unique and vulnerable treatment subgroup [9, 10] . An US registry study of 579 elderly patients diagnosed with PCNSL in the 1990s revealed that the median survival was only 7 months and WBRT alone was the most common treatment modality (46%) [11] . To date, a systematic summary of the research efforts to optimize therapy for elderly PCNSL patients is missing. Therefore, we conducted a systematic review and individual patient data meta-analysis to comprehensively investigate prognosis and treatment strategies for elderly patients with newly diagnosed PCNSL.
patients and methods systematic review of the literature
We included any study that focused on first-line therapy and outcome in exclusively immunocompetent PCNSL patients ≥60 years. We searched Medline, EMBASE, and the Cochrane Library from database initiation until November 2014. We also searched annual meeting abstracts of the following societies (2010-2014): European hematology association (EHA), American Society of Clinical Oncology (ASCO), and American Society of Hematology (ASH). Two investigators (VG and BK) independently reviewed potentially eligible titles, abstracts and full texts if eligible. We asked all primary investigators of eligible studies to provide individual patient data.
individual patient data meta-analysis
Individual patient data from the identified studies were pooled with published and unpublished data of elderly PCNSL patients from international collaborators to maximize generalizability and statistical power. Anonymized patient data were collected using a prespecified case report form. The Research Ethics Committee of the University of Basel approved this study.
end point definitions
Main end points of our individual patient data meta-analysis were: (i) overall survival (OS, defined as time from diagnosis until death due to any cause or date of last follow-up visit) and (ii) progression-free survival (PFS, defined as time from diagnosis until progression, relapse, or death; whichever occurred first, or date of last follow-up visit). Further end points included: complete remission (CR), partial remission (PR), stable disease (SD), and progressive disease (PD). We considered the response status as reported in the publications or as provided by the cooperating investigators. Clinical apparent neurological side-effects were defined as any significant and progressive neurological deterioration in the absence of disease progression developing at any time after start of treatment.
investigated treatments
Patients were categorized as follows: (i) HD-MTX-based therapies [defined as any therapy that contained HD-MTX (>1 g/m 2 )] versus no HD-MTX (including those only receiving WBRT); (ii) HD-MTX monotherapy versus HD-MTX plus any other chemotherapy, (iii) HD-MTX in combination with oral chemotherapy only versus HD-MTX plus at least two other i.v. agents (aggressive) (steroids were not considered as a single agent); and (iv) HD-MTX-based therapy with WBRT versus HD-MTXbased therapy without WBRT. We restricted our investigations to these four categories to address basic therapeutic principles and to preserve sufficient numbers of patients and events. We did not investigate the association between rituximab and the respective outcomes, because the follow-up times in patients receiving rituximab was much shorter compared with those not receiving it, preventing reliable conclusion.
statistical analysis
We used multivariable Cox regression analysis with a random effect for study/database for all prognostic analyses, which were conducted on the complete dataset. In sensitivity analyses, we restricted our analysis to patients being diagnosed after 1997 or to prospective studies. For exploratory purposes, we additionally analyzed survival within different time periods of diagnosis (periods of 10 years). Follow-up was estimated using the inverse KaplanMeier method [12] . We used Kaplan-Meier plots, logistic, and Cox regression models to compare the different treatment regimens with respect to response rate, PFS, and OS. Each analysis was adjusted for age, KPS (≥70% versus <70%), and a random effect for study/database was added. The impact of WBRT on OS and PFS was not investigated using the Cox regression model, because of severe violation of the proportional hazards assumption. For all treatment regimens, we additionally investigated whether the association between treatment and outcome differed by KPS status and tested possible interactions. The impact of WBRT on neurological side-effects was investigated using random-effect logistic regression adjusted for the factors mentioned above. P < 0.05 (two-sided) was considered significant. Further details about methods and statistical analyses are provided in the supplementary Material S1, available at Annals of Oncology online.
results

studies identified by the systematic review
We identified 20 eligible studies published between 1996 and 2014 including 1103 patients (supplementary Figure S2 , available at Annals of Oncology online) [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . Detailed characteristics of identified studies, applied therapies, and outcomes are summarized in Table 1 . In 13/20 (65%) studies, patient data were collected from more than one center [13, 15-18, 21, 23, 25-27, 29-31] ; of those, 8 (62%) were planned prospectively [15, 16, 18, 25-27, 30, 31] . The assessment of the methodological quality of studies is provided in supplementary Material S3, available at Annals of Oncology online. Only three studies (15%) reported neurocognitive outcomes as measured with the mini-mentalstate examination tool [13, 30, 33] . Patient recruitment for the only identified randomized trial (N = 98) has recently been completed and preliminary data were presented in abstract form [25] . This phase II trial suggests that HD-MTX plus procarbazine and vincristine followed by cytarabine (MPV-A) may be more effective compared with HD-MTX plus temozolomide regarding response, PFS, and OS (Table 1) with similar toxicities (≥grade 3 toxicities 72% versus 71%); however, the differences were not statistically significant. The investigators also evaluated neurocognitive outcomes and quality of life, but they were not reported in the abstract [25] . The publication by Roth et al. reported data of the subgroup of elderly PCNSL patients (≥70 years) who were enrolled in the randomized G-PCNSL-SG-1 trial, which was not specifically designed for elderly patients [26] . One German multicenter single-arm study including patients ≥65 years of age recently completed recruitment of 112 patients, but no data have yet been published (NCT00989352).
individual patient data meta-analysis patient characteristics. From the identified 20 studies, 405 (40%) individual patient data [13, 14, 17-21, 23, 24, 30, 33, 34] were available for our individual patient data meta-analysis and pooled with 378 published and unpublished patient data from 6 other databases (Milan N = 9 [35] , N = 18 [36] , N = 183 [37] , N = 36 [4] Figure S2 , available at Annals of Oncology online). Two hundred sixty-one of 783 (33%) patient data were collected in prospective studies, 67% were collected in retrospective studies. Patients' characteristics are summarized in Table 2 . Applied treatment regimens varied widely and are listed in detail in the supplementary Material S4, available at Annals of Oncology online) (only patients included in the individual patient data meta-analysis). Overall, WBRT monotherapy was the most common treatment modality (13%), followed by HD-MTX monotherapy (9%). Patients being diagnosed after 1997 (N = 552) were mostly treated with HD-MTX monotherapy (10%), second most frequent treatment was HD-MTX plus oral chemotherapy (9%). Table 3 summarizes the results from the multivariable analyses for OS. A KPS ≥70% was significantly associated with improved survival. Other factors such as involvement of deep brain structures, cerebrospinal fluid protein elevation, and serum lactate dehydrogenase had no impact on OS or PFS (supplementary Material S5, available at Annals of Oncology online). Our sensitivity analyses conditional on time of diagnosis (diagnosed after 1997) and study design also supported the strong prognostic value of KPS (data not shown).
prognostic factors
cause of death
Of those 508 (65%) patients who died, causes of death were PCNSL in 310 (61%), treatment-related complications in 34 (7%), sepsis in 25 (5%) of patients. Twenty-one patients (4%) died of other causes. Cause of death was unknown in 118 (23%) deceased patients.
response to treatment 2 ) was independently associated with improved OS compared with therapies without HD-MTX (N = 210), which also included WBRT monotherapy (Table 4) [unadjusted 12-and 24-month OS rates: 63% (95% CI 59% to 67%) versus 47% (95% CI 40% to 53%) and 49% (95% CI 44% to 53%) versus 29% (95% CI 23% to 36%), respectively- Figure 2A ]. This association was consistent throughout KPS subgroups and in the subpopulation of patients not receiving any WBRT during first-line treatment. Sensitivity analysis based on patients being diagnosed after 1997 revealed similar results. There was also a positive association regarding PFS without statistical significance (adjusted HR 0.80, 95% CI 0.61-1.04, P = 0.100). In the unadjusted analysis, patients treated with HD-MTX plus any other chemotherapy [median HD-MTX applications 4, interquartile range (IQR) 2-5] only tended to have an improved prognosis compared with HD-MTX monotherapy (median HD-MTX applications 3, IQR 1-7) ( Figure 2B ) [unadjusted 12-and 24-month OS rates: 64% (95% CI 0.60% to 0.68%) versus 57% (95% CI 0.44% to 0.67%) and 50% (96% CI 0.45% to 0.55%) versus 41% (95% CI 0.29% to 0.53%)]. However, the association was statistically significant in the adjusted multivariable analysis (Table 4) and also in our sensitivity analyses restricted to patients being diagnosed after 1997 (adjusted HR 0.63, 95% CI 0.45-0.89) or treated within prospective studies (adjusted HR 0.39, 95% CI 0.21-0.71). Furthermore, HD-MTX plus other chemotherapy was significantly associated with improved PFS (adjusted HR 0.39, 95% CI 0.27-0.58, P < 0.001). Therapies combining HD-MTX plus at least two other i.v. agents (aggressive, median HD-MTX applications 3, IQR 2-4) were not associated with improved OS compared with HD-MTX plus oral chemotherapy only (e.g. HD-MTX combined with temozolomide or procarbazine, median HD-MTX applications 6, IQR 3-8) (Table 4) [unadjusted 12-and 24-month OS rates: 65% (95% CI 56% to 72%) versus 65% (95% CI 57% to 71%) and 50% (95% CI 51% to 58%) versus 50% (95% CI 42% to 58%)] ( Figure 2C ). In patients with a KPS ≥70% HD-MTX plus oral chemotherapy showed a trend for better OS [unadjusted 12-and 24-month OS rates: 78% (95% CI 66% to 86%) versus 73% (95% CI 64% to 83%) and 66% (95% CI 53% to 77%) versus 56% (95% CI 44% to 66%); log-rank test P = 0.0926], but the tested interaction was not significant. The sensitivity analyses restricted to patients being diagnosed after 1997 or treated in prospective studies revealed similar results. There was no difference regarding PFS (adjusted HR 1.26, 95% CI 0.80-1.99).
Overall, the addition of WBRT in those patients being treated with any HD-MTX-based chemotherapy (with WBRT, median HD-MTX applications 4, IQR 2-6; without WBRT, median HD-MTX applications 4, IQR 2-4) was associated with an OS benefit ( Figure 2D) [unadjusted 12-and 24-month OS rates: 78% (95% CI 70% to 85%) versus 59% (95% CI 54% to 63%) and 59% (95% CI 50% to 68%) versus 46% (95% CI 41% to 51%); (log-rank test P = 0.116). Further details are provided in supplementary Figure S7 , available at Annals of Oncology online.
WBRT and neurological side-effects
Two hundred seventy-six of 783 (35%) patients received WBRT as part of first-line therapy (median 36 Gy, range 28.5-70 Gy); 140 of 276 (51%) received a dose of more than 36 Gy. In total, 65 of 783 (8.3%) patients were reported to have clinical apparent neurological side-effects. In 91 cases (12.3%), no explicit information about neurological side-effects was available. The remaining 627 patients (80.1%) were reported as being free of neurological side-effects. Whole-brain radiotherapy was independently associated with an increased risk for neurological side-effects (adjusted odds ratio 5.23, 95% CI 2.33-11.74, P < 0.001). Of those 136 patients who were treated with <36 Gy, 38 (28%) developed neurological side-effects (missing information about neurological side-effects, 24%), whereas of those patients being treated with more than 36 Gy, 14% developed neurotoxicity (missing information about neurological side-effects, 12%). 
salvage therapies
discussion
To our knowledge, this is the largest systematic review and individual patient data meta-analysis of the therapeutic management and outcome of elderly patients with PCNSL. Results revealed an improvement of prognosis over the last decade. Among a wide variety of treatment approaches for elderly patients with newly diagnosed PCNSL, HD-MTX-based therapies were associated with significantly better results. High-dose MTX in combination with at least two other i.v. drugs (aggressive) compared with HD-MTX plus oral chemotherapy were not associated with improved response or survival. In those patients that received HD-MTXbased chemotherapy, WBRT was associated with improved PFS, OS, but also with an increased risk of neurological side-effects. Given the lack of standardized neurological testing and poor reporting of this outcome, definite conclusions about the magnitude of this association are difficult to draw.
Although large in scale, our study has limitations. First, the predominant retrospective nature of the dataset implies inconsistent data quality throughout the different data sources. For example, information about different baseline characteristics crucial for calculation of the "International Extranodal Lymphoma Study Group (IELSG)" score was missing. Consequently, only a restricted number of patients were included in the multivariable analysis to test the prognostic discrimination of components of the IELSG score; thus, these results should be cautiously interpreted. The issue of missing data does not only apply to baseline variables, central pathology review, and information about co-morbidities, but also to acute toxicities during, reasons for treatment termination, and causes of death. In addition, we were not able to include all patients from eligible studies in our individual patient data meta-analysis and had to restrict our investigations of the associations between different treatment regimens and outcome to a limited number. This was necessary to preserve a sufficient number of patients and events in each chosen treatment category to obtain reliable conclusions. However, to maximize generalizability, we included additional patient data from other databases and accounted for the heterogeneity of data sources in our analysis. In particular, the prognostic analyses proved robust in our sensitivity analysis focusing on prospective studies and year of diagnosis. The definition of neurological side-effects was broad and not based on formal cognitive testing, because we a priori assumed that neurological testing was standardized in the minority of studies. Therefore, assuming that only severe forms of clinically apparent neurological side-effects were reported, it is likely that the actual rate of patient impairment due to neurological side-effects is higher than reported herein. Moreover, information on other risk factors, e.g. use of anticonvulsant drugs or pre-existing cerebral vasculopathy, were not available and effects on neurological status could not be addressed. Interpretation of response rates in association with different therapies also needs to consider the limitation of nonstandardized response criteria throughout pooled study data. The cutoff of 60 years was chosen, because it is the lowest reported [7, 9] . In addition, it is also in line with other recent trials for elderly patients suffering from systemic NHL [38] . In univariable analysis, there was a clear association between increasing age and decreased survival probability. However, if adjusted for KPS, only some evidence remained indicating that age above 75 is associated with a worse survival prognosis compared with patients younger than 65 years of age. As reported previously [39] , KPS equal or above 70% is of high prognostic relevance, which we could confirm in our analyses. These findings indicate, that categorization only by age alone is not informative enough to make therapeutic decisions or to define trial eligibility criteria in elderly PCNSL patients; a more appropriate approach is to at least consider both, age and clinical performance status as already implemented in an currently ongoing multicenter PCNSL trial (NCT01011920).
Methotrexate is now the most widely studied drug in the treatment of PCNSL and its efficacy has been demonstrated in several prospective trials [40] [41] [42] . Our results confirm these findings also for the subgroup of elderly PCNSL patients. However, 14% of patients in our database were treated with WBRT only, which is lower than previous reports based on US SEER registry data (46%) [11] . This discrepancy may be explained by the fact that patients included in our analyses were mostly treated at tertiary referral centers and not in the community [11] . Another explanation could be that therapy and outcome of those only being treated with WBRT were not published. Importantly, after 1997 the number of patients treated with WBRT monotherapy substantially declined and HD-MTX-based therapy was the predominant therapy of choice. A more aggressive approach consisting of HD-MTX and at least two other i.v. agents was not associated with improved response or OS compared with HD-MTX plus oral chemotherapy. This may be explained by the fact that these aggressive approaches also included anthracyclines and vincristine, both are well known to be highly active in systemic NHL, but their questionable activity in PCNSL has been reported before [43] [44] [45] . Even if some activity of these agents is assumed, the chosen combinations do not seem to be feasible, because patients receiving this aggressive approach had less HD-MTX applications (median 3) compared with HD-MTX plus oral chemotherapy (median 6).
There were some discrepancies between PFS and OS estimates in our analyses. Usually, one would rather expect significant effects on PFS, but not on OS, e.g. due to limited statistical power. In our analysis, power was not an issue, but rather the fact that patients who received HD-MTX-based chemotherapy more often received salvage treatment, which likely improved OS. Therefore, salvage therapy should always be considered, because it seems that also elderly can benefit from it even after an early relapse. However, to investigate this in further detail, more clinical information at time of relapse would have been needed.
Beside HD-MTX, there is yet no defined standard treatment of newly diagnosed PCNSL as is for instance rituximab-CHOP for systemic NHL [40] . The only phase II randomized trial specifically designed for elderly PCNSL patients suggests that MPV-A may be more effective compared with HD-MTX plus temozolomide [25] ; however, the differences regarding response, PFS, or OS were not statistically significance. Still, the MPV-A regimen can be recommended for further development in the treatment of elderly PCNSL patients.
A recent US multicenter single-arm study (N = 52) showed promising results regarding long-term disease control and low rates of neurotoxicity by using the R-MPV regimen, followed by low-dose WBRT (23.4 Gy) and cytarabine as consolidation [46] . Another recent single-arm study (N = 42) investigated the combination of rituximab, HD-MTX, and temozolomide for induction followed by consolidation with etoposide and cytarabine; WBRT was omitted from the primary treatment strategy [47] . Both studies also showed good outcomes in the small subgroups of patients ≥60 years of age [46, 47] .
Elderly patients exhibit increased risk for neurological sideeffects when exposed to WBRT [8, 48] . In two retrospective series, WBRT in combination with chemotherapy was not associated with improved OS in PCNSL patients treated with HD-MTX, but led to improved disease control [37, 49] . Similarly, in another retrospective analysis, patients older than 60 years of age who were treated with HD-MTX did not seem to benefit from WBRT regarding OS [50] . In all mentioned studies, prevalence of neurological side-effects was not based on standardized testing, but on a broad definition similar to ours. In contrast to these studies, our data suggest that WBRT may improve OS in patients with a lower KPS. Patients with a higher KPS do not seem to benefit. Given the trade-off between a potentially small survival benefit and the risk of neurological side-effects, which still maybe underestimated in these elderly patients, we urge caution regarding the interpretation of WBRT being a superior treatment in addition to HD-MTX this subgroup.
In conclusion, this study provides a comprehensive summary of the available evidence for the first-line treatment and prognosis of elderly PCNSL patients. HD-MTX-based therapy should be offered to these frail patients, whenever possible. Especially, first-line treatment with combinations of HD-MTX with oral alkylating agents are advisable (e.g. HD-MTX plus procarbazine or temozolomide) and deserve to be further investigated. WBRT may improve outcome, but is significantly associated with increased risk for neurological side-effects. Prospective trials designed for elderly PCNSL patients are promptly needed. 
